News from celladon corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Dec 11, 2013, 08:30 ET Celladon Corporation Announces Receipt of EMA Scientific Advice for MYDICAR® and Initiation of AGENT-HF Trial

 Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the...


Nov 18, 2013, 16:58 ET Celladon Corporation Announces Oral Presentation at American Heart Association of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure

 Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the...


Oct 18, 2013, 08:30 ET Celladon Corporation Appoints Michael Narachi as Chairman of the Board of Directors

Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field...


Oct 11, 2013, 08:28 ET Celladon Corporation Files Registration Statement for Proposed Initial Public Offering

Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field...


Sep 26, 2013, 11:20 ET Celladon Corporation Announces Publication of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure

 Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the...


Sep 10, 2013, 08:08 ET Celladon Corporation Announces Appointment of Gregg Alton and Graham Cooper to its Board of Directors

 Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the...


Jul 30, 2013, 07:30 ET Celladon Corporation Announces Pre-clinical Study Demonstrating Inhalable MYDICAR Reverses Pulmonary Arterial Hypertension (PAH)

Celladon Corporation, a clinical-stage biotechnology company committed to applying its first-mover, leadership position in the field of SERCA...


May 29, 2013, 16:00 ET Celladon Corporation Selected as Winner of Red Herring's "Top 100 North America Tech Startup"

Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases...


May 08, 2013, 09:00 ET Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"

 Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular...


May 07, 2013, 12:00 ET Celladon Corporation is a Finalist for the 2013 Red Herring Top 100 North America Award

 Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular...


Mar 29, 2013, 07:00 ET Celladon Corporation To Present at BioCentury Future Leaders in the Biotech Industry Conference

Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases,...


Jan 23, 2013, 08:30 ET Celladon Corporation Receives Notice of Allowance from United States Patent and Trademark Office

Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases,...


Dec 11, 2012, 16:30 ET Celladon Corporation Announces First European Patient Dosed in CUPID Phase 2b Trial of MYDICAR® for Advanced Heart Failure

Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases,...


Oct 02, 2012, 06:00 ET Lonza and Celladon Announce Manufacturing Agreement for MYDICAR®

Lonza, a global leader in the field of viral therapy manufacturing, and Celladon Corporation, a biopharmaceutical company focused on the discovery...


Sep 19, 2012, 09:00 ET Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech

Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases,...


Aug 29, 2012, 09:30 ET Celladon Corporation Announces First Patient Dosed in CUPID Phase 2b Trial of MYDICAR® for Advanced Heart Failure

 Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular...


Jul 19, 2012, 09:00 ET Celladon Corporation Receives Patent from United States Patent and Trademark Office

 Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular...


Jun 18, 2012, 09:15 ET Celladon Corporation Receives Notice of Allowance from European Patent Office

 Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular...


Feb 15, 2012, 09:00 ET Celladon Corporation Completes $43 Million Financing to Advance MYDICAR® for the Treatment of Heart Failure

Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases,...


Dec 12, 2011, 10:00 ET Celladon Corporation Receives FDA Fast Track Designation for Its Investigational Agent MYDICAR® for the Treatment of Heart Failure

 Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases,...


May 23, 2011, 10:00 ET Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Reduction in Clinical Events in Patients for 18 Months Compared with Placebo

Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today...


Mar 23, 2010, 08:00 ET Celladon Corporation Receives Notice of Allowance by U.S. Patent and Trademark Office for Broad Patent Covering Lead Drug Candidate MYDICAR(R)

Celladon Corp. announced today that the United States Patent and Trademark Office (USPTO) has granted a notice of allowance for a broad patent...


May 28, 2009, 15:15 ET Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting

Phase 1 Data Demonstrate Safety and Evidence of Biological Activity in 9 of 12 Patients; Phase 2 Study Currently Enrolling in 17 Leading U.S....


May 26, 2009, 10:51 ET Celladon Corporation Announces Presentation of First-in-Human Gene Transfer to Treat Heart Failure at the 12th Annual Meeting of the American Society of Gene Therapy

Phase 1/2 Calcium Upregulation by Percutaneous Administration (CUPID) Data Highlight Safety Profile and Biological Effects of SERCA2a Enzyme...


Apr 08, 2009, 08:30 ET The Journal of Cardiac Failure Publishes Results From Celladon Corporation's First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure

Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID Trial) Demonstrated Safety and Biological Effects of...